PRaG-1

Phase 2Small molecule

SSecond Affiliated Hospital of Soochow University

PRaG-1 is one of 86 small molecule programs targeting Treatment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TreatmentNot yet recruiting

Patients With Solid TumorsRecruiting

TreatmentPhase 2

Not yet recruiting

Patients With Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

332 competitors in Treatment

#DrugCompanyPhaseTrials

Alfenta

Jazz Pharmaceuticals

Preclinical

1 2

Levulan

Sun Pharmaceutical Industries, Inc.

Preclinical

1 3

Lamprene

Novartis

Preclinical

1 4

Emtriva

Gilead

Preclinical

1 5

Hivid

CConrado Roberto Hoffmann Filho

Preclinical

6 6

Foscavir

CClinigen, Inc.

Preclinical

6 7

PRaG-1

SSecond Affiliated Hospital of Soochow University

Phase 2

1 8

Clomid

Ferring

Preclinical

1 9

Aurlumyn

BBTG International Inc.

Preclinical

1 10

Reminyl

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Treatment1 trial

Immune Modulation With PRaG-1 Treatment

Not yet recruiting·SSecond Affiliated Hospital of Soochow University·Phase 2·NCT07002502·19 enrolled

Patients With Solid Tumors1 trial

Evaluation of the Effect of Cordycepin on CD8+ Lymphocytopenia in Patients With Solid Tumors

Recruiting·SSecond Affiliated Hospital of Soochow University·Phase 2·NCT07258160·127 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for PRaG-1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PRaG-1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PRaG-1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital of Soochow University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSecond Affiliated Hospital of Soochow University

PRaG-1

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Treatment1 trial

Patients With Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News